AURO-CEFPROZIL TABLET
Valsts: Kanāda
Valoda: angļu
Klimata pārmaiņas: Health Canada
Produkta apraksts
(SPC)
22-09-2020
Daži šī produkta dokumenti pašlaik nav pieejami. Varat nosūtīt pieprasījumu mūsu klientu apkalpošanas dienestam, un mēs jums paziņosim, tiklīdz mēs tos varēsim iegūt.
Nosūtīt pieprasījumu.
Nosūtīt pieprasījumu.
Aktīvā sastāvdaļa:
CEFPROZIL
Pieejams no:
AURO PHARMA INC
ATĶ kods:
J01DC10
SNN (starptautisko nepatentēto nosaukumu):
CEFPROZIL
Deva:
250MG
Zāļu forma:
TABLET
Kompozīcija:
CEFPROZIL 250MG
Ievadīšanas:
ORAL
Vienības iepakojumā:
100
Receptes veids:
Prescription
Ārstniecības joma:
SECOND GENERATION CEPHALOSPORINS
Produktu pārskats:
Active ingredient group (AIG) number: 0127613003; AHFS:
Autorizācija statuss:
APPROVED
Autorizācija datums:
2010-04-09
Produkta apraksts
Page 1 of 28
PRODUCT MONOGRAPH
PR
AURO-CEFPROZIL
(Cefprozil)
Tablets 250 mg & 500 mg
USP
ANTIBIOTIC
AURO PHARMA INC.
3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8,
Canada.
Date of Revision:
September 22, 2020
Submission control No.: 243286
Page 2 of 28
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
6
DRUG INTERACTIONS
.........................................................................................................
8
DOSAGE AND ADMINISTRATION
.....................................................................................
8
OVERDOSAGE
........................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY.
................................................................... 9
STORAGE AND STABILITY
..............................................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 11
PART II: SCIENTIFIC INFORMATION
............................................................................
12
PHARMACEUTICAL INFORMATION
..............................................................................
12
CLINICAL TRIALS
..............................................................................................................
13
MICROBIOLOGY
............
Izlasiet visu dokumentu
